Having completed my BSc in Pharmacology and Innovative Therapeutics at Queen Mary University of London in 2018, I joined the whiteford Lab in November of that year. I am now completing my PhD on the identification of a novel therapeutic target to halt angiogenesis in diabetic retinopathy and other neovascular eye diseases.